Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Novel Insight Into Migraine Pathophysiolgy and Galcanezumab Mechanisms of Action
NCT04271202Phase 4Completed
- Sponsor
- Beth Israel Deaconess Medical Center
- Start
- Jul 2020
- Primary completion
- Nov 2023
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 4 trial of galcanezumab in migraine, sponsored by Beth Israel Deaconess Medical Center. Started Jul 2020; status: completed.
02
Drugs
galcanezumab
03
Conditions
migraine
Beyond the preview
Go deeper on NCT04271202.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04271202.